Clinical trial · Observational
The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
The Sanderson Study: A Diagnostic Case-Control Study for the Development of Multiomics Blood Tests for Cancer Screening in a Real World Setting
NCT05516927CI-TRIAL-00082293completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Newly-diagnosed Cancers | — | UNRESOLVED | — |
| Non-cancer Controls | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Freenome Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer Group
- description
- * Collect Subject Data * Collect Blood Specimen
- interventionNames
- Diagnostic Test: Freenome Test
- label
- Non-cancer Group
- description
- * Collect Subject Data * Collect Blood Specimen
- interventionNames
- Diagnostic Test: Freenome Test
Primary outcomes (1)
- measure
- Comparison of Blood Samples from Cancer Case and Non-cancer Control Participants
- timeFrame
- 12 months
- description
- To compare blood samples from cancer case and non-cancer control subjects in order to develop and characterize blood-based multiomics tests in specific cancer types or in a combination of multiple cancers.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
Show eligibility criteria text
Key Inclusion Criteria: * Age ≥30 years within 30 days of enrollment * Able and willing to provide blood samples per protocol * Able to comprehend and willing to sign and date the informed consent and HIPAA * Authorization documents * Able and willing to allow existing health data to be utilized for study purposes Key Exclusion Criteria: * Any history of solid organ or bone marrow transplantation * Any physical trauma or surgery requiring inpatient overnight hospitalization in the 30 days preceding enrollment * Received a blood transfusion in the 30 days preceding enrollment * A medical condition that, in the opinion of the Investigator, should preclude enrollment in the study * Known to be pregnant * Any therapy for cancer, including but not limited to surgery, chemotherapy, biologic therapy, immunotherapy, and/or radiation therapy in the 5 years preceding enrollment * Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 30 days preceding enrollment * Participated or currently participating in another Freenome-sponsored clinical study * For non-cancer groups: Any previous cancer diagnosis in the 5 years preceding enrollment; OR recurrence of the same primary cancer within any timeframe; OR concurrent diagnosis of multiple primary cancers within any timeframe * For the cancer groups: Any previous cancer diagnosis in the 5 years preceding enrollment, apart from the current cancer diagnosis; OR recurrence of the same primary cancer within any timeframe; OR concurrent diagnosis of multiple primary cancers within any timeframe
References
Publications (0)
Data not yet available
No reference posted for this study.